Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Chromosomal Instability In Cell-Free DNA As A Highly Specific Biomarker For Detection Of Ovarian Cancer In Women With Adnexal Masses
A. Vanderstichele, P. Busschaert, D. Smeets, C. Landolfo, E. van Nieuwenhuysen, K. Leunen, P. Neven, F. Amant, S. Mahner, E. Braicu, R. Zeilinger, A. Coosemans, D. Timmerman, D. Lambrechts, I. Vergote
Published 2016 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Purpose: Chromosomal instability is a hallmark of ovarian cancer. Here, we explore copy-number alteration (CNA) profiling in cell-free DNA as a potential biomarker to detect malignancy in patients presenting with an adnexal mass. Experimental Design: We prospectively enrolled 68 patients with an adnexal mass, of which 57 were diagnosed with invasive or borderline carcinoma and 11 with benign disease. Cell-free DNA was extracted from plasma and analyzed by low-coverage whole-genome sequencing. Results: Patterns of chromosomal instability were detectable in cell-free DNA using 44 healthy individuals as a reference. Profiles were representative of those observed in matching tumor tissue and contained CNAs enriched in two large datasets of high-grade serous ovarian cancer (HGSOC). Quantitative measures of chromosomal instability, referred to as genome-wide z-scores, were significantly higher in patients with ovarian carcinoma than in healthy individuals or patients with benign disease. Cell-free DNA testing improved malignancy detection (AUC 0.89) over serum CA-125 (AUC 0.78) or the risk of malignancy index (RMI, AUC 0.81). AUC values of cell-free DNA testing even further increased for HGSOC patients specifically (AUC 0.94). At a specificity of 99.6%, a theoretical threshold required for ovarian cancer screening, sensitivity of cell-free DNA testing was 2- to 5-fold higher compared with CA-125 and RMI testing. Conclusions: This is the first study evaluating the potential of cell-free DNA for the diagnosis of primary ovarian cancer using chromosomal instability as a read-out. We present a promising method to increase specificity of presurgical prediction of malignancy in patients with adnexal masses. Clin Cancer Res; 23(9); 2223–31. ©2016 AACR.
This paper references
Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing
E. Heitzer (2013)
Fast and accurate short read alignment with BurrowsWheeler transform
H Li (2009)
Lambrechts, I. Vergote Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases
A Vanderstichele (2012)
A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
I. Jacobs (1990)
Epithelial Ovarian Cancer: Rationale for Changing the One-Fits-All Standard Treatment Regimen to Subtype-Specific Treatment
E. Despierre (2014)
I. Judson (1993)
Building Predictive Models in R Using the caret Package
M. Kuhn (2008)
Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies
D. Bianchi (2015)
Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer.
E. Schütz (2015)
Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study.
P. Vandenberghe (2015)
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
M. Murtaza (2013)
Ovarian cancer screening and early detection in the general population.
J. A. Rauh-Hain (2011)
Personalized Circulating Tumor DNA Biomarkers Dynamically Predict Treatment Response and Survival In Gynecologic Cancers
E. Pereira (2015)
The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
V. Nossov (2008)
Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis.
E. Meys (2016)
Allele-specific copy number analysis of tumors
P. Van Loo (2010)
Global cancer statistics, 2012
L. Torre (2015)
Stratifying tumour subtypes based on copy number alteration profiles using next-generation sequence data
A. Gusnanto (2015)
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 2015;387:945–56
IJ Jacobs (2017)
ACOG Practice Bulletin. Management of adnexal masses.
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
S. Buys (2011)
Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies
J. Kaijser (2013)
Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver
C. Emmanuel (2014)
DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly.
I. Scheinin (2014)
Ovarian cancer screening—Current status, future directions☆
U. Menon (2014)
Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
S. Xia (2015)
Fast and accurate short read alignment with Burrows–Wheeler transform
Heng Li (2009)
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
I. Jacobs (2016)
Emerging landscape of oncogenic signatures across human cancers
Giovanni Ciriello (2013)
The Sequence Alignment/Map format and SAMtools
Heng Li (2009)
The detection and implication of genome instability in cancer
L. Pikor (2013)
Somatic copy number alterations predict response to platinum therapy in epithelial ovarian cancer.
E. Despierre (2014)
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
J. Chien (2015)
Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing.
F. Amant (2015)
Integrated Genomic Analyses of Ovarian Carcinoma
D. Bell (2011)
Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis.
J. Kaijser (2014)
Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing
Rebecca J. Leary (2012)
Beanplot: A Boxplot Alternative for Visual Comparison of Distributions
P. Kampstra (2008)
Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
S. Mohan (2014)
Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group.
D. Timmerman (2016)
Ovarian Cancer: American Cancer Society Atlas of Clinical Oncology
R. Ozols (2003)
ROCR: visualizing classifier performance in R
T. Sing (2005)
This paper is referenced by
Circulating tumor DNA analysis in the era of precision oncology
Rabih Said (2020)
Circulating cell-free DNA and circulating tumor cells, the “liquid biopsies” in ovarian cancer
Xianliang Cheng (2017)
Massively parallel sequencing of cell-free DNA in plasma for detecting gynaecological tumour-associated copy number alteration
M. Nakabayashi (2018)
The emerging links between chromosomal instability (CIN), metastasis, inflammation and tumour immunity
Andréa E. Tijhuis (2019)
Shallow Whole Genome Sequencing on Circulating Cell-Free DNA Allows Reliable Noninvasive Copy-Number Profiling in Neuroblastoma Patients
N. Van Roy (2017)
Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies
B. Davidson (2018)
Differences in ultrasound features of papillations in unilocular‐solid adnexal cysts: a retrospective international multicenter study
C. Landolfo (2018)
Acute Tumor Transition Angle on Computed Tomography Predicts Chromosomal Instability Status of Primary Gastric Cancer: Radiogenomics Analysis from TCGA and Independent Validation
Y. Lai (2019)
Cell‐free tumour DNA testing for early detection of cancer – a potential future tool
G. Barbany (2019)
Liquid Biopsies in Endocrine Neoplasia—A Systematic Review
Theresa R Tonozzi (2019)
Prediction of the treatment response in ovarian cancer: a ctDNA approach
M. Sharbatoghli (2020)
LiquidCNA: tracking subclonal evolution from longitudinal liquid biopsies using somatic copy number alterations
Eszter Lakatos (2021)
Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer
Q. Chen (2019)
Validation of the Performance of International Ovarian Tumor Analysis (IOTA) Methods in the Diagnosis of Early Stage Ovarian Cancer in a Non-Screening Population
W. Froyman (2017)
Potential clinical applications of circulating cell-free DNA in ovarian cancer patients.
Ana Barbosa (2018)
Apports de l’ADN tumoral circulant dans la compréhension et la prise en charge des carcinomes d’origine gynécologique
Roxane Mari (2019)
Implementing liquid biopsies into clinical decision making for cancer immunotherapy
Dagmar Quandt (2017)
Cervical, Ovarian and Endometrial Tumor Markers: Potential Clinical Value.
Carolina Malhone (2019)
Liquid biopsy in Ovarian cancer using Circulating Tumor DNA and Cells: Ready for Prime Time?
D. Asante (2019)
Liquid biopsy in ovarian cancer.
Lydia Giannopoulou (2020)
Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology.
Demosthenes E Ziogas (2018)
miR‐181a overexpression predicts the poor treatment response and early‐progression of serous ovarian cancer patients
Konstantina Panoutsopoulou (2020)
Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease
Roxane Mari (2019)
Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA
Lydia Giannopoulou (2018)
Comparison of Somatic Mutation Profiles Between Formalin-Fixed Paraffin Embedded Tissues and Plasma Cell-Free DNA from Ovarian Cancer Patients Before and After Surgery
Marianna Jagelková (2020)
Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
Xiaoji Chen (2019)
Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells
U. Testa (2018)
Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors.
C. Landolfo (2020)
Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
B. Li (2019)
Early Detection of Ovarian Cancer.
K. Elias (2018)
Non-invasive Technology Advances in Cancer—A Review of the Advances in the Liquid Biopsy for Endometrial and Ovarian Cancers
M. Openshaw (2020)